These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 29259100)

  • 1. mGluR5 antagonism increases autophagy and prevents disease progression in the
    Abd-Elrahman KS; Hamilton A; Hutchinson SR; Liu F; Russell RC; Ferguson SSG
    Sci Signal; 2017 Dec; 10(510):. PubMed ID: 29259100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of mTOR and CREB pathways following mGluR5 blockade contribute to improved Huntington's pathology in zQ175 mice.
    Abd-Elrahman KS; Ferguson SSG
    Mol Brain; 2019 Apr; 12(1):35. PubMed ID: 30961637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease.
    Doria JG; de Souza JM; Andrade JN; Rodrigues HA; Guimaraes IM; Carvalho TG; Guatimosim C; Dobransky T; Ribeiro FM
    Neurobiol Dis; 2015 Jan; 73():163-73. PubMed ID: 25160573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autophagy is increased following either pharmacological or genetic silencing of mGluR5 signaling in Alzheimer's disease mouse models.
    Abd-Elrahman KS; Hamilton A; Vasefi M; Ferguson SSG
    Mol Brain; 2018 Apr; 11(1):19. PubMed ID: 29631635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabotropic Glutamate Receptor 5 Antagonism Reduces Pathology and Differentially Improves Symptoms in Male and Female Heterozygous zQ175 Huntington's Mice.
    Li SH; Colson TL; Abd-Elrahman KS; Ferguson SSG
    Front Mol Neurosci; 2022; 15():801757. PubMed ID: 35185467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabotropic glutamate receptor 5 knockout promotes motor and biochemical alterations in a mouse model of Huntington's disease.
    Ribeiro FM; Devries RA; Hamilton A; Guimaraes IM; Cregan SP; Pires RG; Ferguson SS
    Hum Mol Genet; 2014 Apr; 23(8):2030-42. PubMed ID: 24282028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mGluR5 regulates REST/NRSF signaling through N-cadherin/β-catenin complex in Huntington's disease.
    de Souza JM; Abd-Elrahman KS; Ribeiro FM; Ferguson SSG
    Mol Brain; 2020 Aug; 13(1):118. PubMed ID: 32859226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabotropic Glutamate Receptor 2/3 Activation Improves Motor Performance and Reduces Pathology in Heterozygous zQ175 Huntington Disease Mice.
    Li SH; Colson TL; Abd-Elrahman KS; Ferguson SSG
    J Pharmacol Exp Ther; 2021 Oct; 379(1):74-84. PubMed ID: 34330748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ULK1-mediated phosphorylation of ATG14 promotes autophagy and is impaired in Huntington's disease models.
    Wold MS; Lim J; Lachance V; Deng Z; Yue Z
    Mol Neurodegener; 2016 Dec; 11(1):76. PubMed ID: 27938392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VGLUT3 Deletion Rescues Motor Deficits and Neuronal Loss in the zQ175 Mouse Model of Huntington's Disease.
    Ibrahim KS; El Mestikawy S; Abd-Elrahman KS; Ferguson SSG
    J Neurosci; 2023 Jun; 43(23):4365-4377. PubMed ID: 37055181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabotropic glutamate receptor 5 as a potential therapeutic target in Huntington's disease.
    Ribeiro FM; Hamilton A; Doria JG; Guimaraes IM; Cregan SP; Ferguson SS
    Expert Opin Ther Targets; 2014 Nov; 18(11):1293-304. PubMed ID: 25118797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington's disease.
    Luis-Ravelo D; Estévez-Silva H; Barroso-Chinea P; Afonso-Oramas D; Salas-Hernández J; Rodríguez-Núñez J; Acevedo-Arozena A; Marcellino D; González-Hernández T
    Exp Neurol; 2018 Jan; 299(Pt A):137-147. PubMed ID: 29056363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative Electroencephalographic Analysis Provides an Early-Stage Indicator of Disease Onset and Progression in the zQ175 Knock-In Mouse Model of Huntington's Disease.
    Fisher SP; Schwartz MD; Wurts-Black S; Thomas AM; Chen TM; Miller MA; Palmerston JB; Kilduff TS; Morairty SR
    Sleep; 2016 Feb; 39(2):379-91. PubMed ID: 26446107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington's disease.
    Doria JG; Silva FR; de Souza JM; Vieira LB; Carvalho TG; Reis HJ; Pereira GS; Dobransky T; Ribeiro FM
    Br J Pharmacol; 2013 Jun; 169(4):909-21. PubMed ID: 23489026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous immunoglobulin ameliorates motor and cognitive deficits and neuropathology in R6/2 mouse model of Huntington's disease by decreasing mutant huntingtin protein level and normalizing NF-κB signaling pathway.
    Liu SY; Yu XL; Zhu J; Liu XM; Zhang Y; Dong QX; Ma S; Liu RT
    Brain Res; 2018 Oct; 1697():21-33. PubMed ID: 29902468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic Pharmacological mGluR5 Inhibition Prevents Cognitive Impairment and Reduces Pathogenesis in an Alzheimer Disease Mouse Model.
    Hamilton A; Vasefi M; Vander Tuin C; McQuaid RJ; Anisman H; Ferguson SS
    Cell Rep; 2016 May; 15(9):1859-65. PubMed ID: 27210751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive deficits in transgenic and knock-in HTT mice parallel those in Huntington's disease.
    Farrar AM; Murphy CA; Paterson NE; Oakeshott S; He D; Alosio W; McConnell K; Menalled LB; Ramboz S; Park LC; Howland D; Brunner D
    J Huntingtons Dis; 2014; 3(2):145-58. PubMed ID: 25062858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Behavioral, Neuropathological, Brain Metabolic and Key Molecular Changes in zQ175 Knock-In Mouse Model of Huntington's Disease.
    Peng Q; Wu B; Jiang M; Jin J; Hou Z; Zheng J; Zhang J; Duan W
    PLoS One; 2016; 11(2):e0148839. PubMed ID: 26859386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lycium barbarum polysaccharide attenuates the cytotoxicity of mutant huntingtin and increases the activity of AKT.
    Fang F; Peng T; Yang S; Wang W; Zhang Y; Li H
    Int J Dev Neurosci; 2016 Aug; 52():66-74. PubMed ID: 27196502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ellagic acid rescues motor and cognitive deficits in the R6/2 mouse model of Huntington's disease by lowering mutant huntingtin protein.
    Sun X; Zhu J; Sun XY; Ji M; Yu XL; Liu RT
    Food Funct; 2020 Feb; 11(2):1334-1348. PubMed ID: 32043503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.